Aurothiomalate-Based Drugs as Potentially Novel Agents Against Leishmania major: A Mini Review

Acta Parasitol. 2022 Jun;67(2):640-647. doi: 10.1007/s11686-022-00536-2. Epub 2022 Apr 5.

Abstract

Purpose: Leishmaniasis is a major public health problem worldwide in many parts of the world. Current anti-leishmanial drugs have only limited clinical efficacy. Aurothiomalate derivatives are useful for treating rheumatoid arthritis, but have emerged as a promising therapeutic candidate for leishmaniasis. This paper gives a review of the literature about the usefulness of aurothiomalate derivatives against leishmaniasis.

Methods: In this study, we reviewed the proposed mechanisms of action of aurothiomalate and related compounds on the metabolism of L. major and collected data by searching relevant articles.

Results: Aurothiomalate-based drugs could be effective against leishmaniasis through two direct and indirect mechanisms: first, cytotoxic effects on parasites via thiomalate's false substrate role in the citric acid cycle against malate; and second, immunosuppressive and anti-inflammatory effects of aurothiomalate derivatives with prostaglandin production inhibitory effects.

Conclusions: The current study documented that aurothiomalate-based drugs could be effective against leishmaniasis through two direct and indirect mechanisms of action. Gold thiomalate as a promising hit should be evaluated against L. major in vitro and in vivo conditions in the future.

Keywords: Anti-leishmanial activity; Aurothiomalate; Fumarate hydratase; Leishmaniasis; S-2-thiomalate.

Publication types

  • Review

MeSH terms

  • Gold Sodium Thiomalate / metabolism
  • Gold Sodium Thiomalate / pharmacology
  • Gold Sodium Thiomalate / therapeutic use
  • Humans
  • Leishmania major*
  • Leishmaniasis* / drug therapy

Substances

  • Gold Sodium Thiomalate